Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2024  > 
Branch of Organ Transplantation of Chinese Medical Association, . Guideline for clinical diagnosis and treatment of tuberculosis in kidney transplant recipients in China (2023 edition)[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024098
Citation: Branch of Organ Transplantation of Chinese Medical Association, . Guideline for clinical diagnosis and treatment of tuberculosis in kidney transplant recipients in China (2023 edition)[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024098
shu

Guideline for clinical diagnosis and treatment of tuberculosis in kidney transplant recipients in China (2023 edition)

doi: 10.3969/j.issn.1674-7445.2024098

  • Peking University People's Hospital, Beijing 100044, China

More Information
  • Corresponding author: Wang Qiang, Email: wq301135@163.com
  • Received Date: 2024-03-18
    Available Online: 2024-04-01
    Abstract
  • This guideline aims to provide comprehensive and practical guidance for clinical management of tuberculosis in kidney transplant recipients. First, it summarizes the particularity of tuberculosis in kidney transplant recipients, and highlights the high incidence and diverse clinical manifestations. To better understand the patients' conditions, relevant assessment of tuberculosis is recommended before kidney transplantation. Extensive attention should be paid to the monitoring of tuberculosis after kidney transplantation. Regarding the diagnosis, the guideline explicitly introduces common diagnostic approaches for tuberculosis, and evaluates the applicability in kidney transplant recipients. After the diagnosis is confirmed, it discusses how to balance the treatment and rejection of tuberculosis under the background of immunosuppressants, and focuses upon the potential drug interaction. In terms of prevention, it emphasizes the screening of tuberculosis prior to kidney transplantation. This guideline is designed to deepen the understanding of medical staff for tuberculosis management in kidney transplant recipients, promote more effective clinical practice and improve the quality of life of the recipients.

     

    • FullText(HTML)
  • loading
    • References(39)
  • [1]
    World Health Organization. Global tuberculosis report 2018. Geneva: WHO, 2018[EB/OL]. [2023-12-31].https://www.scirp.org/reference/ReferencesPapers?ReferenceID=2479322.
    [2]
    LOPEZ DE CASTILLA D, SCHLUGER NW. Tuberculosis following solid organ transplantation[J]. Transpl Infect Dis, 2010, 12(2): 106-112. DOI: 10.1111/j.1399-3062.2009.00475.x.
    [3]
    HORNE DJ, NARITA M, SPITTERS CL, et al. Challenging issues in tuberculosis in solid organ transplantation[J]. Clin Infect Dis, 2013, 57(10): 1473-1482. DOI: 10.1093/cid/cit488.
    [4]
    OCEBM Levels of Evidence[EB/OL]. [2023-12-31].https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence.
    [5]
    AL-EFRAIJ K, MOTA L, LUNNY C, et al. Risk of active tuberculosis in chronic kidney disease: a systematic review and meta-analysis[J]. Int J Tuberc Lung Dis, 2015, 19(12): 1493-1499. DOI: 10.5588/ijtld.15.0081.
    [6]
    REIS-SANTOS B, GOMES T, HORTA BL, et al. Tuberculosis prevalence in renal transplant recipients: systematic review and meta-analysis[J]. J Bras Nefrol, 2013, 35(3): 206-213. DOI: 10.5935/0101-2800.20130033.
    [7]
    KATRAK S, HAN E, READHEAD A, et al. Solid organ transplant recipients with tuberculosis disease in California, 2010 to 2020[J]. Am J Transplant, 2023, 23(3): 401-407. DOI: 10.1016/j.ajt.2022.11.019.
    [8]
    SUBRAMANIAN AK, MORRIS MI, AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis infections in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4): 68-76. DOI: 10.1111/ajt.12100.
    [9]
    BUMBACEA D, AREND SM, EYUBOGLU F, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement[J]. Eur Respir J, 2012, 40(4): 990-1013. DOI: 10.1183/09031936.00000712.
    [10]
    SUN HY. Treating tuberculosis in solid organ transplant recipients[J]. Curr Opin Infect Dis, 2014, 27(6): 501-505. DOI: 10.1097/QCO.0000000000000102.
    [11]
    AGUADO JM, TORRE-CISNEROS J, FORTÚN J, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology[J]. Clin Infect Dis, 2009, 48(9): 1276-1284. DOI: 10.1086/597590.
    [12]
    SUBRAMANIAN A, DORMAN S, AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis in solid organ transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 4): S57-S62. DOI: 10.1111/j.1600-6143.2009.02894.x.
    [13]
    VIANA LA, CRISTELLI MP, SANTOS DW, et al. Influence of epidemiology, immunosuppressive regimens, clinical presentation, and treatment on kidney transplant outcomes of patients diagnosed with tuberculosis: a retrospective cohort analysis[J]. Am J Transplant, 2019, 19(5): 1421-1431. DOI: 10.1111/ajt.15220.
    [14]
    SINGH N, PATERSON DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management[J]. Clin Infect Dis, 1998, 27(5): 1266-1277. DOI: 10.1086/514993.
    [15]
    TORRE-CISNEROS J, DOBLAS A, AGUADO JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort[J]. Clin Infect Dis, 2009, 48(12): 1657-1665. DOI: 10.1086/599035.
    [16]
    KANWAL S, AKHTAR AM, AHMED A. Factors associated with mortality to drug-resistant tuberculosis and their programmatic management in treatment centres of Punjab, Pakistan[J]. J Pak Med Assoc, 2017, 67(6): 858-862.
    [17]
    RAFIEI N, WILLIAMS J, MULLEY WR, et al. Mycobacterium tuberculosis: active disease and latent infection in a renal transplant cohort[J]. Nephrology (Carlton), 2019, 24(5): 569-574. DOI: 10.1111/nep.13386.
    [18]
    KANABALAN RD, LEE LJ, LEE TY, et al. Human tuberculosis and mycobacterium tuberculosis complex: a review on genetic diversity, pathogenesis and omics approaches in host biomarkers discovery[J]. Microbiol Res, 2021, 246: 126674. DOI: 10.1016/j.micres.2020.126674.
    [19]
    PENA T, KLESNEY-TAIT J. Mycobacterial infections in solid organ and hematopoietic stem cell transplantation[J]. Clin Chest Med, 2017, 38(4): 761-770. DOI: 10.1016/j.ccm.2017.07.011.
    [20]
    BOYD R, FORD N, PADGEN P, et al. Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis[J]. Int J Tuberc Lung Dis, 2017, 21(11): 1173-1180. DOI: 10.5588/ijtld.17.0230.
    [21]
    THERON G, ZIJENAH L, CHANDA D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial[J]. Lancet, 2014, 383(9915): 424-435. DOI: 10.1016/S0140-6736(13)62073-5.
    [22]
    MACLEAN E, KOHLI M, WEBER SF, et al. Advances in molecular diagnosis of tuberculosis[J]. J Clin Microbiol, 2020, 58(10): e01582-19. DOI: 10.1128/JCM.01582-19.
    [23]
    KOHLI M, SCHILLER I, DENDUKURI N, et al. Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance[J]. Cochrane Database Syst Rev, 2018, 8(8): CD012768. DOI: 10.1002/14651858.CD012768.pub2.
    [24]
    王雅娟, 曹新益, 刘升明. 宏基因组二代测序和GeneXpert MTB/RIF对结核病诊断价值的Meta分析[J]. 中国防痨杂志, 2022, 44(12): 1327-1337. DOI: 10.19982/j.issn.1000-6621.20220303.

    WANG YJ, CAO XY, LIU SM. Meta-analysis of the diagnostic value of metagenomic next-generation sequencing and GeneXpert MTB/RIF in tuberculosis[J]. Chin J Antituberc, 2022, 44(12): 1327-1337. DOI: 10.19982/j.issn.1000-6621.20220303.
    [25]
    HAAS MK, BELKNAP RW. Diagnostic tests for latent tuberculosis infection[J]. Clin Chest Med, 2019, 40(4): 829-837. DOI: 10.1016/j.ccm.2019.07.007.
    [26]
    HEYMANN WR. The hydroxychloroquine-interferon gamma release assay question: TB or not TB?[J]. J Am Acad Dermatol, 2019, 80(4): 902-903. DOI: 10.1016/j.jaad.2019.01.070.
    [27]
    BENNET R, NEJAT S, ERIKSSON M. Effective tuberculosis contact investigation using interferon-gamma release assays[J]. Pediatr Infect Dis J, 2019, 38(4): e76-e78. DOI: 10.1097/INF.0000000000002272.
    [28]
    WU X, CHEN P, WEI W, et al. Diagnostic value of the interferon-γ release assay for tuberculosis infection in patients with Behçet's disease[J]. BMC Infect Dis, 2019, 19(1): 323. DOI: 10.1186/s12879-019-3954-y.
    [29]
    DIEL R, GOLETTI D, FERRARA G, et al. Interferon-γ release assays for the diagnosis of latent mycobacterium tuberculosis infection: a systematic review and meta-analysis[J]. Eur Respir J, 2011, 37(1): 88-99. DOI: 10.1183/09031936.00115110.
    [30]
    中华医学会放射学分会传染病放射学组, 中国医师协会放射医师分会感染影像专业委员会, 中国研究型医院学会感染与炎症放射专业委员会, 等. 肺结核影像诊断标准[J/OL]. 新发传染病电子杂志, 2021, 6(1): 1-6. DOI: 10.19871/j.cnki.xfcrbzz.2021.01.001.

    Infectious Disease Radiology Group of Branch of Radiology of Chinese Medical Association, Infection Imaging Professional Committee of Branch of Radiologists of Chinese Medical Doctor Association, Infection and Inflammatory Radiology Professional Committee of Chinese Research Hospital Association, et al. Imaging diagnostic criteria for pulmonary tuberculosis[J/OL]. Electr J Emerg Infect Dis, 2021, 6(1): 1-6. DOI: 10.19871/j.cnki.xfcrbzz.2021.01.001.
    [31]
    中华医学会结核病学分会, 结核病病理学诊断专家共识编写组. 中国结核病病理学诊断专家共识[J]. 中华结核和呼吸杂志, 2017, 40(6): 419-425. DOI: 10.3760/cma.j.issn.1001-0939.2017.06.005.

    Branch of Tuberculosis of Chinese Medical Association, Expert Consensus Writing Group for Pathological Diagnosis of Tuberculosis. Expert consensus on pathological diagnosis of tuberculosis in China[J]. Chin J Tuberc Respir Dis, 2017, 40(6): 419-425. DOI: 10.3760/cma.j.issn.1001-0939.2017.06.005.
    [32]
    SOROHAN BM, ISMAIL G, TACU D, et al. Mycobacterium tuberculosis infection after kidney transplantation: a comprehensive review[J]. Pathogens, 2022, 11(9): 1041. DOI: 10.3390/pathogens11091041.
    [33]
    SUBRAMANIAN AK, THEODOROPOULOS NM, Infectious Diseases Community of Practice of the American Society of Transplantation. Mycobacterium tuberculosis infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American Society of Transplantation[J]. Clin Transplant, 2019, 33(9): e13513. DOI: 10.1111/ctr.13513.
    [34]
    中国防痨协会. 耐药结核病化学治疗指南(2019年简版)[J]. 中国防痨杂志, 2019, 41(10): 1025-1073. DOI: 10.3969/j.issn.1000-6621.2019.10.001.

    Anti-Tuberculosis Association of China. Guidelines for chemotherapy of drug-resistant tuberculosis (2019 edition)[J]. Chin J Antituberc, 2019, 41(10): 1025-1073. DOI: 10.3969/j.issn.1000-6621.2019.10.001.
    [35]
    JINDANI A, NUNN AJ, ENARSON DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial[J]. Lancet, 2004, 364(9441): 1244-1251. DOI: 10.1016/S0140-6736(04)17141-9.
    [36]
    BURMAN WJ, GALLICANO K, PELOQUIN C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials[J]. Clin Pharmacokinet, 2001, 40(5): 327-341. DOI: 10.2165/00003088-200140050-00002.
    [37]
    金弢. 含利福平方案治疗结核病时需用免疫抑制剂的剂量调整(附3例报告)[J]. 中国防痨杂志, 2018, 40(9): 1007-1011. DOI: 10.3969/j.issn.1000-6621.2018.09.020.

    JIN T. Dose adjustment of immunosuppressants in anti-tuberculosis regimen containing rifampins (report of three cases)[J]. Chin J Antituberc, 2018, 40(9): 1007-1011. DOI: 10.3969/j.issn.1000-6621.2018.09.020.
    [38]
    HE Q, BU F, WANG Q, et al. Examination of the impact of CYP3A4/5 on drug-drug interaction between schizandrol a/schizandrol b and tacrolimus (FK-506): a physiologically based pharmacokinetic modeling approach[J]. Int J Mol Sci, 2022, 23(9): 4485. DOI: 10.3390/ijms23094485.
    [39]
    YAN L, YANG ZQ, SHI YY, et al. Effects of Wuzhi capsules on blood concentration of tacrolimus in renal transplant recipients[J]. Ann Transplant, 2019, 24: 594-604. DOI: 10.12659/AOT.918980.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (58) PDF downloads(24) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return